Literature DB >> 33915696

Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.

Jesse O'Shea1, Mark R Prausnitz2, Nadine Rouphael1.   

Abstract

Vaccines are an essential component of pandemic preparedness but can be limited due to challenges in production and logistical implementation. While vaccine candidates were rapidly developed against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), immunization campaigns remain an obstacle to achieving herd immunity. Dissolvable microneedle patches are advantageous for many possible reasons: improved immunogenicity; dose-sparing effects; expected low manufacturing cost; elimination of sharps; reduction of vaccine wastage; no need for reconstitution; simplified supply chain, with reduction of cold chain supply through increased thermostability; ease of use, reducing the need for healthcare providers; and greater acceptability compared to traditional hypodermic injections. When applied to coronavirus disease 2019 (COVID-19) and future pandemic outbreaks, microneedle patches have great potential to improve vaccination globally and save many lives.

Entities:  

Keywords:  dissolvable microneedle patch; drug delivery; equity; skin vaccination; vaccine delivery

Year:  2021        PMID: 33915696     DOI: 10.3390/vaccines9040320

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  9 in total

1.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 2.  Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.

Authors:  Jasmin Hassan; Charlotte Haigh; Tanvir Ahmed; Md Jasim Uddin; Diganta B Das
Journal:  Pharmaceutics       Date:  2022-05-16       Impact factor: 6.525

3.  Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.

Authors:  Khue G Nguyen; Siena M Mantooth; Maura R Vrabel; David A Zaharoff
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

4.  Mucosal and transdermal vaccine delivery strategies against COVID-19.

Authors:  Ashwini Kumar; Awanish Kumar
Journal:  Drug Deliv Transl Res       Date:  2021-05-15       Impact factor: 5.671

Review 5.  The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination.

Authors:  Rayen Yanara Valdivia-Olivares; Maria Rodriguez-Fernandez; María Javiera Álvarez-Figueroa; Alexis M Kalergis; José Vicente González-Aramundiz
Journal:  Vaccines (Basel)       Date:  2021-12-01

Review 6.  Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.

Authors:  Robert Langer; Pieter R Cullis; Olivia M Merkel; Mark R Prausnitz; Hagar I Labouta; Yasmine Gomaa; Sara S Nogueira; Tushar Kumeria
Journal:  Drug Deliv Transl Res       Date:  2022-03-15       Impact factor: 5.671

Review 7.  Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.

Authors:  Ihab Mansoor; Heba A Eassa; Kamilia H A Mohammed; Marwa A Abd El-Fattah; Marwa H Abdo; Eman Rashad; Hadeer A Eassa; Asmaa Saleh; Omnya M Amin; Mohamed Ismail Nounou; Ola Ghoneim
Journal:  AAPS PharmSciTech       Date:  2022-04-05       Impact factor: 4.026

Review 8.  Current Vaccine Platforms in Enhancing T-Cell Response.

Authors:  Takehiro Ura; Masaki Takeuchi; Tatsukata Kawagoe; Nobuhisa Mizuki; Kenji Okuda; Masaru Shimada
Journal:  Vaccines (Basel)       Date:  2022-08-21

9.  The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.

Authors:  Senta M Kapnick
Journal:  DNA Cell Biol       Date:  2021-12-24       Impact factor: 3.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.